Extended Data Fig. 5: Catalase reduces breast cancer extravasation to lung in obese hosts.
a, Representative immunofluorescence image for data shown in Fig. 5c. LF + veh, n = 5 mice; LF + cat, n = 4 mice; HF + veh, n = 5 mice; HF + cat, n = 4 mice. b, Schematic illustration of the in vivo extravasation assay corresponding to Fig. 5d. LF or HF mice were injected via tail vein with syngeneic breast cancer cells labelled with a green fluorescent CellTracker, treated with either vitamin E or vehicle and extravasation was quantified in lung after 48h via fluorescence microscopy. c, Representative immunofluorescence image for data shown in Fig. 5f. LF + veh, n = 6 mice; LF + cat, n = 4 mice; HF + veh, n = 8 mice; HF + cat, n = 8 mice. d, Schematic illustration of the in vivo extravasation assay corresponding to Fig. 5g,h. WT or ob/ob mice were injected via tail vein with syngeneic breast cancer cells labelled with a green fluorescent CellTracker, treated with either catalase or vehicle and extravasation was quantified in lung after 48h via fluorescence microscopy. e, Representative immunofluorescence image for data shown in Fig. 5g. WT + veh, n = 9 mice; WT + cat, n = 7 mice; ob/ob + veh, n = 7 mice; ob/ob + cat, n = 4 mice. f, Quantification of TEER across an HMEC monolayer genetically modified to express an shRNA against catalase (shCAT), versus a scramble control (shSCR). n = 4 Transwells per condition representing individual experimental replicates with similar results; mean ± SEM; two-tailed Student’s t-test.
